Organon & Co. (NYSE:OGN) Given Consensus Rating of “Reduce” by Analysts

10 Jun 2026, 12:38 by Sarita Garza · The Markets Daily

Organon & Co. (NYSE:OGN – Get Free Report) has been given an average recommendation of “Reduce” by the seven analysts that are covering the firm, MarketBeat.com reports. Two equities research analysts have rated the stock with a sell recommendation and five have assigned a hold recommendation to the company. The average 1-year price target among brokers that have covered the stock in the last year is $11.40.

Several research firms have recently weighed in on OGN. Piper Sandler upgraded shares of Organon & Co. from an “underweight” rating to a “neutral” rating and lifted their target price for the stock from $5.00 to $14.00 in a research note on Tuesday, April 28th. BNP Paribas Exane reaffirmed a “neutral” rating and set a $14.00 price objective (up from $12.00) on shares of Organon & Co. in a research note on Wednesday, April 29th. Weiss Ratings raised shares of Organon & Co. from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Friday, May 15th. Barclays boosted their price objective on shares of Organon & Co. from $7.50 to $8.00 and gave the company an “underweight” rating in a research note on Tuesday, February 24th. Finally, Zacks Research raised shares of Organon & Co. from a “strong sell” rating to a “hold” rating in a research note on Tuesday, April 14th.

Check Out Our Latest Stock Analysis on Organon & Co.

Insider Buying and Selling

In other news, SVP Lynette Holzbaur acquired 26,448 shares of Organon & Co. stock in a transaction that occurred on Wednesday, May 6th. The stock was bought at an average price of $13.35 per share, with a total value of $353,080.80. Following the completion of the purchase, the senior vice president owned 52,851 shares in the company, valued at approximately $705,560.85. The trade was a 100.17% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this link. Corporate insiders own 1.62% of the company’s stock.

Institutional Investors Weigh In On Organon & Co.

Hedge funds have recently bought and sold shares of the stock. Foster Dykema Cabot & Partners LLC bought a new stake in Organon & Co. during the third quarter valued at approximately $29,000. Rothschild Investment LLC lifted its position in Organon & Co. by 73.1% during the third quarter. Rothschild Investment LLC now owns 3,899 shares of the company’s stock valued at $42,000 after purchasing an additional 1,646 shares during the last quarter. Farther Finance Advisors LLC lifted its position in Organon & Co. by 87.8% during the fourth quarter. Farther Finance Advisors LLC now owns 4,349 shares of the company’s stock valued at $31,000 after purchasing an additional 2,033 shares during the last quarter. Smartleaf Asset Management LLC lifted its position in Organon & Co. by 70.2% during the third quarter. Smartleaf Asset Management LLC now owns 5,113 shares of the company’s stock valued at $53,000 after purchasing an additional 2,109 shares during the last quarter. Finally, Eurizon Capital SGR S.p.A. bought a new stake in Organon & Co. during the fourth quarter valued at approximately $44,000. 77.43% of the stock is currently owned by institutional investors.

Organon & Co. Stock Up 0.0%

Organon & Co. stock opened at $13.40 on Wednesday. The company has a current ratio of 1.97, a quick ratio of 1.42 and a debt-to-equity ratio of 9.47. The firm’s fifty day moving average price is $11.16 and its two-hundred day moving average price is $8.77. Organon & Co. has a 1-year low of $5.69 and a 1-year high of $13.48. The firm has a market capitalization of $3.52 billion, a price-to-earnings ratio of 14.40, a price-to-earnings-growth ratio of 1.24 and a beta of 1.55.

Organon & Co. (NYSE:OGN – Get Free Report) last released its quarterly earnings results on Thursday, April 30th. The company reported $0.71 earnings per share for the quarter, missing analysts’ consensus estimates of $0.83 by ($0.12). Organon & Co. had a net margin of 3.99% and a return on equity of 99.95%. The firm had revenue of $1.46 billion for the quarter, compared to the consensus estimate of $1.49 billion. During the same period in the previous year, the business earned $1.02 earnings per share. The firm’s revenue for the quarter was down 3.5% on a year-over-year basis. On average, equities research analysts predict that Organon & Co. will post 3.23 earnings per share for the current fiscal year.

Organon & Co. Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, June 11th. Investors of record on Monday, May 11th will be paid a dividend of $0.02 per share. The ex-dividend date of this dividend is Monday, May 11th. This represents a $0.08 annualized dividend and a yield of 0.6%. Organon & Co.’s payout ratio is currently 8.60%.

Organon & Co. Company Profile

(Get Free Report)

Organon & Co is a global healthcare company that was established as an independent, publicly traded entity following its spin-off from Merck & Co in June 2021. Headquartered in Jersey City, New Jersey, Organon focuses on delivering therapeutic solutions across women’s health, biosimilars, and established brands. The company’s creation reflected a strategic effort to concentrate on specialty pharmaceuticals and legacy products with proven patient impact.